Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net income was USD 55.09 million compared to net loss of USD 68.36 million a year ago. Basic earnings per share from continuing operations was USD 21.42 compared to basic loss per share from continuing operations of USD 206.38 a year ago. Diluted earnings per share from continuing operations was USD 0.09 compared to diluted loss per share from continuing operations of USD 206.38 a year ago.